N/A N=318 The Role of Emotional Processing in Improving the Quality of Life of Breast Cancer Patients
Breast Cancer Female · Depressive Symptoms · Fatigue
Primary: Depression Depression — 10.82; 11.57; 9.86; 11.23 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=52 Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors
Solid Tumor, Adult
Primary: Immune-related Objective Response Rate — 9 Participants
N/A N=446 Post-chemotherapy Symptom Management SMART
Cancer
Primary: Symptom Severity Index- Comparison of Two Groups Created by First Randomization — 24.53; 25.86 score on a scale — p=.31
Phase 2 N=8 Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy
Facioscapulohumeral Muscular Dystrophy (FSHD)
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 8; 0 Participants
Phase 3 N=475 Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia
COVID-19 · Lung Infection
Primary: Supplemental Oxygen Requirement — 139; 132; 91; 101 Participants — p=0.391
Phase 4 N=302 Alcohol Drinkers' Exposure to Preventive Therapy for TB (ADEPTT)
Tuberculosis · HIV/AIDS · Alcohol Abuse
Primary: Cumulative Incidence of Participants Experiencing a Grade 3/4 Hepatotoxicity — 8.3 percent
Phase 3 N=533 Mite Asthma Pediatric Immunotherapy Trial
Allergic Asthma Due to Dermatophagoides Farinae · Allergic Asthma Due to Dermatophagoides Pteronyssinus · Allergic Rhinitis Due to House Dust Mite
Primary: Annualized Rate of Clinically Relevant Asthma Exacerbations — 0.18; 0.21 Exacerbations per year per participant — p=0.5412
N/A N=25 Robotically Augmented Mental Practice
Stroke
Primary: MEP Amplitude — 0.813; 0.475; 0.916; 1.237 mV — p=>0.00238
Phase 3 N=525 Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico
Healthy Volunteers (Meningococcal Infection)
Primary: Percentage of Participants With Antibody Titers Greater Than or Equal to (>=) 1:8 Against Meningococcal Serogroups A, C, Y, and W Following Last Vaccination With MenACYW…
Phase 1 N=35 Behavioral Pharmacology of THC and D-limonene
D-limonene and THC Pharmacodynamics
Primary: Mean Peak Change From Baseline Anxiety as Assessed by the Drug Effect Questionnaire (DEQ) — -1.2; 13.8; 18.7; -1.9 score on a scale
Phase 2 N=15 Effectiveness of Onabotulinumtoxin A (Botox) in Pediatric Patients Experiencing Migraines: A Study in the Pediatric Pain Population
Migraine Disorders · Headache, Migraine · Pediatrics
Primary: Frequency of Migraines — 28; 20; 28 days — p=0.038
N/A N=41 Using Physical Tracking to Predict Sunburn
Prevention
Primary: Prevalence of Sun Protection Practices — 0.30; 0.43; 0.35; 0.41 proportion of practices/day
Early Phase 1 N=12 Peripheral Benzodiazepine Receptors (PBR28) Brain PET Imaging With Lipopolysaccharide Challenge for the Study of Microglia Function in Alzheimer's Disease
Alzheimer Disease
Primary: Microglial Activation Reserve Index (MARI) — 17.7; 30.1 percentage of MARI — p=0.14
Phase 1 N=20 Gut Butyrate and Blood Pressure in African Americans
Hypertension
Primary: Mean Daytime Blood Pressure — 137.5; 132.9; 128.2 mmHg
Phase 2 N=17 A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis
Dermatitis, Atopic
Primary: Mean Percentage Change From Baseline in EASI Score at Week 16 — -83.1; -92.3 Percentage change